Replication-defective recombinant influenza virus for simultaneously expressing HA and HEF

A technology for replication-deficient influenza virus, applied in the field of preparation of recombinant influenza virus, which can solve the problems of virulence reversal mutation, poor antigenicity, and long development cycle of cold-adapted virus strains, so as to maintain immunogenicity and strong mucosal immunity Response and cellular immune response levels, effects of strong and long-lasting immunogenicity
CN109097341AActive Publication Date: 2018-12-28QINGDAO AGRI UNIV
12 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
QINGDAO AGRI UNIV
Publication Date
2018-12-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a preparation method of a replication-defective A and D divalent influenza virus attenuated live vaccine. The invention constructs a recombinant virus strain; on the premise ofnot changing gene stability, the constructed recombinant virus can stably and simultaneously express surface protein hemagglutinin HA of A type influenza virus H1N1 subtype and unique surface proteinhemagglutinin esterase fusion protein HEF of D type influenza virus. The constructed attenuated strain has good gene stability and cannot be replicated in an experimental animal body, so the constructed attenuated strain has no pathogenicity; meanwhile, the constructed attenuated strain also can induce a body to produce strong mucosal immune response and cellular immune response level and keeps intense and durable immunogenicity. The key is that a vaccine candidate strain can produce an immunoprotection action on the A type influenza virus H1N1 subtype and the D type influenza virus. Therefore, the replication-defective A and D divalent influenza virus attenuated live vaccine has huge social significance in preventing and controlling A type and D type influenza.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of research and development of influenza virus vaccine technology, in particular to the preparation of a recombinant influenza virus capable of simultaneously expressing the surface protein hemagglutinin HA of type A influenza virus H1N1 and the fusion protein HEF of the only surface protein hemagglutinin esterase of type D influenza virus Methods and uses. Background technique

[0002] Influenza is an infectious disease that is caused by influenza virus (Influenza Virus) and seriously endangers the respiratory system of humans and animals. Influenza viruses are divided into three types (IAV, IBV, ICV) according to their nucleoprotein antigenicity differences, and the influenza viruses that infect humans are mainly types A and B. Influenza D virus (IDV) is a new type of influenza virus discovered in recent years, which infects humans and mammals.

[0003] At present, influenza vaccine is the main method to prevent a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More